Selexipag is a pyrazine derivative, specifically N-(methanesulfonyl)-2-{4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetamide, with two phenyl groups at positions 5 and 6 of the pyrazine ring. It is an orphan drug used to treat pulmonary arterial hypertension and functions as a prodrug for ACT-333679. It acts as a prostacyclin receptor agonist, platelet aggregation inhibitor, and vasodilator. Chemically, it is a monocarboxylic acid amide, ether, aromatic amine, tertiary amine, and N-sulfonylcarboxamide. It is functionally related to ACT-333679.
